Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: A study in a real life population

Geriatrics and Gerontology International

Volumn 11, Issue 3, 2011, Pages 256-261

  Van Puyvelde, Katrien ^a   Mets, Tony ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Galantamine; Real life study

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ABDOMINAL PAIN; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; BRADYCARDIA; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO; VOMITING;

AGED; ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; COGNITION; DELAYED-ACTION PREPARATIONS; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; PATIENT SATISFACTION; PHENYLCARBAMATES; PIPERIDINES; TREATMENT OUTCOME;

EID: 79959551785     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00674.x     Document Type: Article

References (24)

1. Lanctot KL, Herrmann N, Yau KK etal. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169: 557-564.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006: CD005593.
3. Raina P, Santaguida P, Ismaila A etal. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-397.
4. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 473-482.
5. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004; 11: 734-741.
6. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006: CD001747.
7. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276.
8. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268.
9. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449.
10. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-595.
11. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000; 60: 1095-1122.
12. Sakurai H, Hanyu H, Kanetaka H etal. Prevalence of coexisting diseases in patients with Alzheimer's disease. Geriatr Gerontol Int 2010; 10: 216-217.
13. Courtney C, Farrell D, Gray R etal. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): randomised double-blind trial. Lancet 2004; 363: 2105-2115.
14. Frisoni GB. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. J Neurol 2001; 248: 551-557.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
17. Kaufer DI, Cummings JL, Ketchel P etal. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233-239.
18. Forette F, Panisset M, Boller F. Clinical trials in cognitive impairment in the elderly. Aging (Milano) 1992; 4: 239-250.
19. Hing JP, Piotrovsky V, Kimko H, Brashear HR, Zhao Q. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005; 21: 483-488.
20. Zhao Q, Janssens L, Verhaeghe T, Brashear HR, Truyen L. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005; 21: 1547-1554.
21. Nieoullon A, Bentue-Ferrer D, Bordet R, Tsolaki M, Forstl H. Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*. Curr Med Res Opin 2008; 24: 3357-3367.
22. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 20: 120-132.
23. Gorus E, Lambert M, De Raedt R, Mets T. The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. J Clin Psychopharmacol 2007; 27: 182-187.
24. Ioannidis JP, Haidich AB, Lau J. Any casualties in the clash of randomised and observational evidence? BMJ 2001; 322: 879-880.